Help eligible INTUNIV patients pay no more than $15 per prescription for up to 6 months*
For patients with ADHD receiving INTUNIV as monotherapy or as adjunctive therapy to stimulant medications1
More than 1 MILLION prescriptions for INTUNIV have been filled since November 20092
When your patients register with intuniv.com they can receive the following INTUNIV resources:
- A coupon to pay no more than $15 per prescription for up to 6 months*
- Access to inTUNE Support Program™ features, including
- E-mail support
- The Progress Tracker
- Appointment &
*If patient total cost per prescription is more than $15, the offer covers the amount above $15 up to a maximum of $60 per prescription, for up to 6 prescriptions. No discount will be allowed for prescription costs paid for entirely by insurance plans, or covered under any federal or state health care programs, including Medicare or Medicaid, as well as any similar federal or state pharmaceutical assistance programs. Other restrictions may apply. See card for details.
- INTUNIV is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications in children and adolescents ages 6 to 17. The effectiveness of INTUNIV for more than 8 weeks has not been systematically evaluated.
Important Safety Information
- Patients with a history of hypersensitivity to INTUNIV, its inactive ingredients, or other products containing guanfacine should not take INTUNIV.
- Hypotension, bradycardia, and syncope were observed in clinical trials. Decreases in blood pressure and heart rate were dose-dependent and were less pronounced over time of treatment. Heart rate and blood pressure should be measured prior to initiation of therapy, following dose increases, and periodically while on therapy. Use INTUNIV with caution in patients with a history of hypotension, heart block, bradycardia, cardiovascular disease, or syncope, or who may have a condition that predisposes them to syncope; are treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope. Advise patients to avoid becoming dehydrated or overheated.
- Somnolence and sedation were commonly reported adverse reactions in clinical studies. The potential for additive sedative effects with CNS depressant drugs should be considered. Caution patients against operating heavy equipment or driving until they know how they respond to INTUNIV. Advise patients to avoid use with alcohol.
- The most common adverse reactions (incidence ≥5% and at least twice the rate for placebo) in the monotherapy trials with INTUNIV were somnolence, fatigue, nausea, lethargy, and hypotension, and in the adjunctive trial with INTUNIV were somnolence, fatigue, insomnia, dizziness, and abdominal pain.
Please see Full Prescribing Information.
- INTUNIV [package insert]. Wayne, PA: Shire US Inc.
- IMS Health National Prescription Audit. July 2011.